Triastek Partners with Johnson & Johnson and Receives Equity Investment for 3D Printed Oral Drugs
On October 9, 2026, Nanjixiong learned that 3D printed pharmaceutical formulation developer Triastek, Inc., based in Nanjing, had signed a collaboration and licensing agreement with Johnson & Johnson to jointly develop new oral medicines. Johnson & Johnson Innovation – JJDC also made an equity investment in Triastek.Founded in 2015, Triastek pioneered Melt Extrusion Deposition (MED) pharmaceutical 3D printing, enabling digital drug development and continuous production. Its platform covers dosage-form design, manufacturing equipment and production processes, with the aim of improving development efficiency and clinical efficacy. The company focuses on an FDM pharmaceutical formulation technology platform.
Recent developments include a new strategic financing round completed in July and an international research and production center in Shanghai. Its first 3D printed drug to reach Phase II clinical trials, D23, has completed patient enrollment. An oral targeted-delivery patent application published in July concerns drug delivery at desired gastrointestinal locations.
Nanjixiong's observation
Johnson & Johnson's decision to collaborate with and invest in Triastek indicates international pharmaceutical recognition of 3D printing's value in oral drug development. It is an important signal for industrial adoption in pharmaceuticals.
Sources: 36Kr; Eastmoney; Dahe Financial Cube.
Original source report
AI-translated from an article by Kuaixiong on Nanjixiong, originally published on 2026-10-09. Text and images retain the original source attribution.
Read the original Chinese article
页:
[1]